240 related articles for article (PubMed ID: 26418879)
21. Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma.
Liao W; Liu W; Liu X; Yuan Q; Ou Y; Qi Y; Huang W; Wang Y; Huang J
Oncotarget; 2015 Sep; 6(27):24132-47. PubMed ID: 26125229
[TBL] [Abstract][Full Text] [Related]
22. Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma.
Zhang HX; Jiang SS; Zhang XF; Zhou ZQ; Pan QZ; Chen CL; Zhao JJ; Tang Y; Xia JC; Weng DS
Oncotarget; 2015 Oct; 6(33):34800-17. PubMed ID: 26430962
[TBL] [Abstract][Full Text] [Related]
23. An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway.
Leng C; Zhang ZG; Chen WX; Luo HP; Song J; Dong W; Zhu XR; Chen XP; Liang HF; Zhang BX
Cancer Lett; 2016 Jun; 376(1):188-96. PubMed ID: 26996299
[TBL] [Abstract][Full Text] [Related]
24. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
[TBL] [Abstract][Full Text] [Related]
25. TTK Inhibitors as a Targeted Therapy for
Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
[TBL] [Abstract][Full Text] [Related]
26. BCA3 contributes to the malignant progression of hepatocellular carcinoma through AKT activation and NF-κB translocation.
Ma D; Li M; Su J; Zhang S
Exp Cell Res; 2018 Jan; 362(1):142-151. PubMed ID: 29133128
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma.
Zhou SL; Dai Z; Zhou ZJ; Wang XY; Yang GH; Wang Z; Huang XW; Fan J; Zhou J
Hepatology; 2012 Dec; 56(6):2242-54. PubMed ID: 22711685
[TBL] [Abstract][Full Text] [Related]
28. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.
Xu MZ; Chan SW; Liu AM; Wong KF; Fan ST; Chen J; Poon RT; Zender L; Lowe SW; Hong W; Luk JM
Oncogene; 2011 Mar; 30(10):1229-40. PubMed ID: 21076472
[TBL] [Abstract][Full Text] [Related]
29. RNA over-editing of BLCAP contributes to hepatocarcinogenesis identified by whole-genome and transcriptome sequencing.
Hu X; Wan S; Ou Y; Zhou B; Zhu J; Yi X; Guan Y; Jia W; Liu X; Wang Q; Qi Y; Yuan Q; Huang W; Liao W; Wang Y; Zhang Q; Xiao H; Chen X; Huang J
Cancer Lett; 2015 Feb; 357(2):510-9. PubMed ID: 25499081
[TBL] [Abstract][Full Text] [Related]
30. Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma.
Ku CY; Liu YH; Lin HY; Lu SC; Lin JY
Oncotarget; 2016 Apr; 7(14):18229-46. PubMed ID: 26919097
[TBL] [Abstract][Full Text] [Related]
31. ATGL promotes the proliferation of hepatocellular carcinoma cells via the p-AKT signaling pathway.
Liu M; Yu X; Lin L; Deng J; Wang K; Xia Y; Tang X; Hong H
J Biochem Mol Toxicol; 2019 Nov; 33(11):e22391. PubMed ID: 31476254
[TBL] [Abstract][Full Text] [Related]
32. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
33. High expression of proline-rich tyrosine kinase 2 is associated with poor survival of hepatocellular carcinoma via regulating phosphatidylinositol 3-kinase/AKT pathway.
Cao J; Chen Y; Fu J; Qian YW; Ren YB; Su B; Luo T; Dai RY; Huang L; Yan JJ; Wu MC; Yan YQ; Wang HY
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S312-23. PubMed ID: 22618716
[TBL] [Abstract][Full Text] [Related]
34. Rho GDP dissociation inhibitor beta promotes cell proliferation and invasion by modulating the AKT pathway in hepatocellular carcinoma.
Fang Y; Yi J; Lizhi L; Qiucheng C
DNA Cell Biol; 2014 Nov; 33(11):781-6. PubMed ID: 25180836
[TBL] [Abstract][Full Text] [Related]
35. The tumor-suppressor gene LZTS1 suppresses hepatocellular carcinoma proliferation by impairing PI3K/Akt pathway.
He Y; Liu X
Biomed Pharmacother; 2015 Dec; 76():141-6. PubMed ID: 26653561
[TBL] [Abstract][Full Text] [Related]
36. POU5F1B promotes hepatocellular carcinoma proliferation by activating AKT.
Pan Y; Zhan L; Chen L; Zhang H; Sun C; Xing C
Biomed Pharmacother; 2018 Apr; 100():374-380. PubMed ID: 29454285
[TBL] [Abstract][Full Text] [Related]
37. Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma.
Liang B; Chen R; Wang T; Cao L; Liu Y; Yin F; Zhu M; Fan X; Liang Y; Zhang L; Guo Y; Zhao J
Clin Cancer Res; 2013 Jun; 19(11):2905-16. PubMed ID: 23549880
[TBL] [Abstract][Full Text] [Related]
38. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
39. CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression.
Cheng Q; Yuan F; Lu F; Zhang B; Chen T; Chen X; Cheng Y; Li N; Ma L; Tong T
Oncotarget; 2015 Mar; 6(7):4733-44. PubMed ID: 25749381
[TBL] [Abstract][Full Text] [Related]
40. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation.
Ching YP; Leong VY; Lee MF; Xu HT; Jin DY; Ng IO
Cancer Res; 2007 Apr; 67(8):3601-8. PubMed ID: 17440071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
